From mass-producing insulin to building pharmaceutical AI “factories,” Lilly’s 150-year North Star remains the same: being in ...

Eli Lilly (NYSE:LLY) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on ...

Novo Nordisk stock rose as it raised its guidance on the back of the strong performance of its weight-loss pill.

Eli Lilly leads GLP-1s but faces rising Novo competition; DCF fair value is $956 vs. $960. Click here to read this latest ...

Eli Lilly's valuation looks far more attractive now than it did even a year ago.

Eli Lilly is coming off an impressive first-quarter performance, with sales soaring by 56%.

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the ...

Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.

The hosts of Morning Brew Daily made a simple argument on a recent episode that the idea of the “Ozempic economy” should be ...

Eli Lilly (LLY) has cemented its status as the world's leading pharmaceutical company as it produced a stellar set of Q1 2026 ...

Eli Lilly (NYSE:LLY | LLY Price Prediction) just delivered one of the strongest first quarters in big pharma history, but ...

Surging consumer demand for blockbuster weight-loss drugs helped offset their declining prices.